Maja Bujas‐Bobanovic

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial

Lawrence A. Leiter, Bertrand Cariou, Dirk Müller‐Wieland et al. · Diabetes Obesity and Metabolism · 2017 · 136 citations · Full text

Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

Kausik K. Ray, Lawrence A. Leiter, Dirk Müller‐Wieland et al. · Diabetes Obesity and Metabolism · 2018 · 94 citations · Full text

Blockade of phencyclidine‐induced effects by a nitric oxide donor

Maja Bujas‐Bobanovic, David C. Bird, H.A. Robertson et al. · British Journal of Pharmacology · 2000 · 86 citations · Full text

Game-based versus traditional case-based learning: comparing effectiveness in stroke continuing medical education.

Deanna Telner, Maja Bujas‐Bobanovic, David W. Chan et al. · PubMed · 2010 · 84 citations · Full text

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials

Kausik K. Ray, Antonio J. Vallejo‐Vaz, Henry N. Ginsberg et al. · Atherosclerosis · 2019 · 66 citations · Full text